Afatinib pharmacokinetics and metabolism after oral administration to healthy male volunteersSTOPFER, Peter; MARZIN, Kristell; NARJES, Hans et al.Cancer chemotherapy and pharmacology. 2012, Vol 69, Num 4, pp 1051-1061, issn 0344-5704, 11 p.Article

L'afatinib (BIBW 2992) = Afatinib (BIBW 2992)PRIM, N; FORE, M; MENNECIER, B et al.Revue de pneumologie clinique (Paris). 2014, Vol 70, Num 5, pp 279-285, issn 0761-8417, 7 p.Article

Phase I study of pulsatile 3-day administration of afatinib (BIBW 2992) in combination with docetaxel in advanced solid tumorsAWADA, A. H; DUMEZ, H; HENDLISZ, A et al.Investigational new drugs. 2013, Vol 31, Num 3, pp 734-741, issn 0167-6997, 8 p.Article

A phase I dose escalation study off BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor I (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumoursESKENS, F. A. L. M; MOM, C. H; DE VRIES, E. G. E et al.British journal of cancer. 2008, Vol 98, Num 1, pp 80-85, issn 0007-0920, 6 p.Article

Emerging Concepts in the Pathology and Molecular Biology of Advanced Non-Small Cell Lung CancerKULESZA, Peter; RAMCHANDRAN, Kavitha; PATEL, Jyoti D et al.American journal of clinical pathology. 2011, Vol 136, Num 2, pp 228-238, issn 0002-9173, 11 p.Article

Phase I study of continuous afatinib (BIBW 2992) in patients with advanced non-small cell lung cancer after prior chemotherapy/erlotinib/gefitinib (LUX-Lung 4)MURAKAMI, H; TAMURA, T; YAMAMOTO, N et al.Cancer chemotherapy and pharmacology. 2012, Vol 69, Num 4, pp 891-899, issn 0344-5704, 9 p.Article

EGFR inhibitors in non-small cell lung cancer (NSCLC): the emerging role of the dual irreversible EGFR/HER2 inhibitor BIBW 2992SPICER, James F; RUDMAN, Sarah M.Targeted oncology. 2010, Vol 5, Num 4, pp 245-255, issn 1776-2596, 11 p.Article

Second-generation irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs): A better mousetrap? A review of the clinical evidenceIGNATIUS OU, Sai-Hong.Critical reviews in oncology/hematology. 2012, Vol 83, Num 3, pp 407-421, issn 1040-8428, 15 p.Article